Q32 BIO INC (QTTB) Stock Analyst Ratings
NASDAQ:QTTB - Nasdaq - US7469641051 - Common Stock
ChartMill assigns a Buy % Consensus number of 80% to QTTB. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 17.75. This target is 436.19% above the current price.
QTTB was analyzed by 11 analysts. The buy percentage consensus is at 80. So analysts seem to be have mildly positive about QTTB.
In the last month the buy percentage fell by 8 points. So the trust of analysts is decreasing.
QTTB was analyzed by 11 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2024-12-12 | Guggenheim | Downgrade | Buy -> Neutral |
| 2024-12-12 | BMO Capital | Maintains | Outperform -> Outperform |
| 2024-12-11 | Leerink Partners | Downgrade | Outperform -> Market Perform |
| 2024-12-11 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2024-12-11 | Wells Fargo | Downgrade | Overweight -> Equal-Weight |
| 2024-12-11 | Raymond James | Downgrade | Strong Buy -> Outperform |
| 2024-12-11 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2024-12-06 | BMO Capital | Initiate | Outperform |
| 2024-10-24 | Raymond James | Initiate | Strong Buy |
| 2024-09-11 | Wells Fargo | Initiate | Overweight |
| 2024-06-17 | Guggenheim | Initiate | Buy |
| 2024-05-21 | Leerink Partners | Initiate | Outperform |
| 2024-04-11 | Oppenheimer | Initiate | Outperform |
| 2024-04-02 | Piper Sandler | Initiate | Overweight |